Community Practice Connections: Medical Crossfire®: How Have HER2-Low Expressing Breast Cancers and Novel Advances in the Field Redefined Care As We Knew It?
Community Practice Connections: Medical Crossfire®: How Have HER2-Low Expressing Breast Cancers and Novel Advances in the Field Redefined Care As We Knew It? is organized by Physicians' Education Resource, LLC (PER).
Release Date: April 28, 2023
Expiration Date: April 28, 2024
Description:
Approximately 60% of HER2-negative metastatic breast cancers express low levels of HER2, yet these cancers have always been defined and treated as HER2-negative, where treatment choice is guided by the hormone receptor (HR) status. However, paradigms are beginning to shift based on evidence indicating that some HER2-targeted agents may benefit patients with lower HER2 expression levels. Practitioners need to be aware of how to identify patients with HER2-low breast cancer and remain up to date with evolving research in the field, including the evidence as well as rationale for utilizing HER2-targeted approaches in patients with HER2-low breast cancer.
This Community Practice Connection™ program provides an in-depth review of some of the key highlights from the Medical Crossfire®: How Have HER2-Low Expressing Breast Cancers and Novel Advances in the Field Redefined Care As We Knew It? satellite symposium held in March 2023. This unique and engaging multimedia activity is ideal for the community-based clinician and focuses on the practical aspects of managing patients with breast cancer and putting recent clinical trial data into context. The program is designed to inform those who did not attend the live meeting and to help reinforce learnings for those who did.
Learning Objectives:
Upon successful completion of this activity, you should be better prepared to:
• Utilize molecular testing approaches to identify patients with HER2-low breast cancer
• Determine recent evidence from clinical trials that have evaluated the efficacy and safety of HER2-targeted strategies among patients with HER2-low breast cancer
• Incorporate recent evidence, in parallel with guideline recommendations, to match tumor- and patient-specific characteristics in devising personalized plans for HER2-low breast cancer
• Develop multidisciplinary methods to facilitate care coordination among teams who treat HER2-low breast cancer to proactively identify and manage treatment-related toxicities